Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | ANCHOR: melphalan flufenamide in R/R myeloma

Roman Hajek • 10 Jun 2021
ASCO 2021
Multiple Myeloma Antibodies Bortezomib Daratumumab Dexamethasone Melflufen

Roman Hajek, MD, PhD, University Hospital Ostrava, Ostrava, Czech Republic, summarizes the Phase II ANCHOR trial (NCT03481556), which investigated melphalan flufenamide (melflufen), a peptide-drug conjugate (PDC), and dexamethasone with either bortezomib or daratumumab in patients with relapsed/refractory (R/R) multiple myeloma. In a group of pretreated patients, the optimal dose of melflufen was determined to be 30 mg and no dose-related toxicities were observed. Recruitment is currently ongoing and additional data will be presented in the future. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

More from Roman Hajek

3:46
IKEMA: isatuximab, carfilzomib and dexamethasone in RRMM
Roman Hajek • 10 Jun 2021

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals